𝙍𝙚𝙩𝙞𝙣𝙖 𝙏𝙤𝙙𝙖𝙮 ’s October issue is a special edition: AI in the Retina Clinic. Chatbots, documentation, the OR, trial screening, and why the goal is a digital copilot, not autopilot. Read the October issue: ow.ly/TqbZ50ZXGAh #Ophthalmology

Jonathan Lin, MD, PhD, is a Rising Star in Retina ⭐️ He trained at Mass Eye and Ear for residency and then at Stanford for fellowship. Read about his path to retina, favorite experiences as a fellow, and pearls for new surgeons: ow.ly/K7jV50ZW3v0

The authors' takeaway: "OCT findings alone may not fully predict functional recovery even when imaging appears severe." To their knowledge, this is the first reported case of thymic carcinoma with CAR. Read the case: retinatoday.com/articles/202… 5/5 5/5

Treatment was aggressive and multimodal: systemic and sub-Tenon corticosteroids, IVIG, plasmapheresis, B-cell depletion therapy, intravitreal corticosteroid implants, and systemic chemotherapy. At 8 months, VA was counting fingers at 7 ft. 4/5 4/5

Two months after vision loss, VA was light perception OU. OCT showed significant EZ loss, severe photoreceptor and outer retinal atrophy, and diffuse retinal thinning in each eye. These are considered poor prognostic indicators. 3/5 3/5

Infectious and laboratory workup was unremarkable. CT revealed an 8.2 x 8.5 x 8 cm anterior mediastinal mass. Biopsy: thymic carcinoma. CAR panel: positive for recoverin, Rab6, aldolase, and enolase. 2/5 2/5

A 54-year-old man presented with painless, bilateral vision loss over 1 week. VA: hand motion OU. Anterior segment unremarkable, no RAPD. Fundus exam: attenuated, sclerotic ghost vessels and temporal disc pallor in each eye. 1/5 1/5

Catch up on the best of Euretina 2026 with our Eyetube video meeting coverage! Learn about gene therapies, TKIs, tamponades, novel retinal implants, and more. Catch up here: ow.ly/5P4C50ZXfHA

Dr. Carl Danzig says picking a treatment is easy—you just have to get patients in the chair who agree to treatment in the first place. What methods does he employ to get patients to where they need to be? Check out the new Eyetube series GA in Practice: ow.ly/LWqZ50ZSJ1E

Supporting patients with GA goes beyond discussing disease progression. Priya Vakharia, MD, FASRS, shares practical strategies for counseling, preparing for functional changes, and helping patients maintain independence throughout their GA journey: ow.ly/2s9T50ZW0LZ

Alexis Warren, MD, is One to Watch in Retina! 🎉 She was inspired to pursue retina as a young child shadowing her father in the clinic. Read about Dr. Warren’s path to retina, her key mentors, and pearls for new surgeons: ow.ly/V0lW50ZUZsn

Most vitreous hemorrhages from a PVD clear on their own—but 17% come with a retinal detachment hiding underneath, most within the first 3 weeks. 👁️ Barton Blackorby, MD; Matt Starr, MD; and Kyle Kovacs, MD, discuss when to watch and when to operate: ow.ly/Bu9P50ZVCn8

How are you integrating advanced imaging and surgical technology into your practice? Kat Talcott, MD, and Jorge Fortun, MD, share how the Zeiss Retina Workflow keeps them organized and efficient in the clinic and OR. Learn more at: ow.ly/exp150ZLAU9 #ad

In PVR surgery, the goal is not only to reattach the retina, but to protect the macula at every step. Surgical pearls from Drs. Shah and Anguita: ow.ly/mI5C50ZVw8P #Ophthalmology #Vitreoretinopathy

When anti-VEGF therapy isn't enough for DME, what comes next? Drs. Pfannenstiel and Clevenger review approved and emerging implant-based treatments for diabetic retinopathy and diabetic macular edema. ow.ly/3cNa50ZUCKq #Retina #DME

We had a blast in Vienna at Euretina 2026! The exhibit hall was bustling, the sessions were packed, and our booth was swarmed! We cannot wait to give out more “We Love Retina” bags at FLORetina in December. #retina #Euretina2026

Which patients with geographic atrophy may be appropriate candidates for complement inhibition? Explore key considerations for treatment selection, including disease characteristics and patient factors: ow.ly/rVgN50ZRzmV This article is available to our ex-US audiences.

Up to 35% of patients with DME gained fewer than 5 letters at 12 weeks on monthly aflibercept 2 mg in the Protocol T early analysis. Where could TKIs fit? ow.ly/yJZh50ZRyio #Ophthalmology

👁️ This World Retina Day, we celebrate the advances shaping retinal care. But can we do more to detect diabetic eye disease earlier? Experts from around the world explore the challenges of global screening—and the opportunities ahead. Read more: ow.ly/nvpM50ZKY1W

Can OCTA predict DR progression? Kallista Zhuang, BA, Shinji Kakihara, MD, PhD, and Amani A. Fawzi, MD review the evidence in Retina Today's Sept issue. Read: ow.ly/VBiH50ZQ9yl #RetinaResearch #Ophthalmology